Ingersoll Rand Inc.

Hello everyone. Thank you for joining us and welcome to Ingersoll Rand's third quarter 2026 earnings call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Max Vorsheimer, Director of Investor Relations. Max, please go ahead.

Thank you for joining Ingersoll Rand's third quarter 2026 earnings call. I'm Max Vorsheimer, Director of Investor Relations, and joining me this morning are Vicente Reynal, our Chairman and CEO, and Vik Kinney, our Chief Financial Officer. Our earnings release and presentation were issued yesterday afternoon and are available on the investor relations section of our website where a replay of this call will also be posted. Before we begin, please note that today's discussion will include forward-looking statements subject to the risks and uncertainties described in our SEC filings and on slide two of this presentation, which you should read in conjunction with the information provided on this call. We will also reference certain non-GAAP financial measures. Reconciliations to the most comparable GAAP financial measures are included in our earnings release and this presentation, both of which are available on the investor relations section of our website. Today, we will review our third quarter results, discuss segment performance, and provide an update to our full year 2026 guidance. During Q&A, please limit yourself to one question and one follow-up to allow time for other participants. With that, I'll turn the call over to Vicente.

Thanks, Max, and good morning to everyone, and thank you for joining today. Beginning on slide three, we delivered robust financial performance in the third quarter, highlighted by 18% organic orders growth, 4% organic revenue growth, and a 17% year-over-year increase in adjusted EPS, excluding the benefit of IEPA tariff refunds received during the quarter. Organic orders growth accelerated across both short to medium cycle and long cycle businesses. including a particularly large engineer to order solution, WIN, that we'll discuss in more detail shortly. Important to know that excluding these large ETO orders, organic orders still grew high single digits. As we will discuss this morning, we're raising our full year revenue and adjusted EPS guidance. The board has also authorized a $2 billion increase to our share repurchase program, providing greater flexibility to compound shareholder value. M&A continues to be our top priority for capital deployment, supported by a robust pipeline of attractive strategic bolt-on opportunities. We're excited about the momentum we're building, including another acquisition that we successfully closed this morning, which I will look forward to sharing more about in a moment. Turning to slide four, underpinning our performance is IRX, or Inc. So Ran Execution Excellence. IRX remains our key enabler of execution, and it is how our teams around the world stay focused on controlling what we can control, supporting our customers, driving productivity and allocating capital effectively. A key strategic imperative of the IRX process, as you can see on the slide, is to deploy talent. Earlier this morning, we announced new leadership appointments. Scott Watson, who was previously leading our life science business, has been named Senior Vice President and Group President of ITS North America and ITS EMEA, and Sean Carlson, who was previously leading our precision technology business, has been named Senior Vice President and Group President of the PST segment. These appointments reflect the growth of our businesses and the depth of our leadership bench. The leadership in these roles will position us to move faster, execute with greater focus, and better serve our customers. I also want to recognize Mike Weathered. who will transition to an advisory role through May 2028 before retiring. A longtime member of our leadership team, Mike helped drive IRX adoption across our company, where it is now very firmly embedded in our culture. We thank him for his many contributions and wish him well in his next chapter. Turning to slide five, I am pleased to share that this morning we closed on the acquisition of IVEC Corporation. a leading provider of small volume precision liquid metering and dispensing systems. The business adds approximately $40 million in annual revenue and will sit within our PST segment, specifically in the life science business. It expands our expertise in key precision pump technologies and strengthens our solution for life science customers and was acquired at a low double digit multiple consistent with our discipline valuation standards. Year to date, we have closed or signed eight transactions and we have an additional seven transactions at the LOI stage. Our funnel remains healthy with more than 200 companies and approximately 90% of our deals continue to be internally sourced. For 2026, we now expect to be approximately 200 to 300 basis points of annualized inorganic revenue. Our 400 to 500 business point target is an average over the cycle and not a single year goal, and it remains unchanged. This year simply reflects transaction timing, not any change in our strategy or the strength of our funnel. Our discipline M&A strategy remains a key differentiator and an important driver of long-term value creation. Now, I will hand it over to Vik, who will review our financial performance.